Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 125

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 125
---
 the Company’s products and processes. Furthermore, regulatory approval,
when obtained, will yield certain types of non-patent exclusivities that can maintain the Company’s advantage even after expiration
of the earlier “basic patent estate”.

<div align='center'>75</div>

We also have additional subsequent
patents that we believe could prevent competitors from entering the market when patents directed to the specific conjugate molecules
expire. The additional patents are directed to manufacturing processes, formulations and other important technologies and serve to support
and extend patent protection beyond the earliest patents. While it is a fact that the earliest patent families are due to expire in the
next few years, we believe that the newest patent applications will provide protection to the updated products and processes for their
manufacture. The latest patent applications, some of which have matured to patents, are designed to protect various improvements to the
earliest filed patents, including improvements to the process of production, and ready to use formulations that may be administered from
pre-filled syringes and do not require addition of activators prior to use.

The latest family of patent
applications is derived from WO 2017/103924 (filed in China and in other territories), and the objectives the Company aims to achieve
with these applications are to seek to obtain patent protection to cover improved compositions which are being used or which may be used
by the Company in the future. The improved compositions that the Company aims to protect with these applications relate to other hydrogels
that are formed using GelrinC’s conjugates of polyethylene glycol and denatured fibrinogen. In particular, the conjugates are generated
using an improved process that avoids the use of potentially harmful polar organic solvents. The family of patent applications derived
from WO 2017/103924 includes patent application Nos. US 17/554720, EP 3389736, CA 3006695, HK 1260187, IN 201827024148, JP 2021-181190
and IL 259891, which are detailed in the table below. A patent in China, CN 108472413, was recently granted, whereas the other patents
in this family are still in different stages of examination. These other patent applications may not mature into actual granted patents.
Thus, there is a risk that if any one or more family members are not granted, the improved compositions will not be patent protected
in their respective territory.

GelrinP

A second “